Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients

Charite University, Berlin, Germany20 enrolled

Overview

This study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (EGCG), in multiple sclerosis patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

Capsules with 160 mg Teavigo (at least 94% EGCG)DIETARY_SUPPLEMENT

Daily intake of 600 mg EGCG for 3 months

PlaceboDIETARY_SUPPLEMENT

Daily intake of placebo capsules for 3 months

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with relapsing-remitting multiple sclerosis * stable treatment with glatiramer acetate at least 6 months prior to inclusion * Expanded disability status scale \< 4.5 * Normal weight, overweight Exclusion Criteria: * Primary or secondary progressive forms of multiple sclerosis * Clinically relevant heart, lung, liver, kidney diseases * Habitual caffeine intake over 300 mg per day * Habitual consumption of green tea * Alcohol or drug abuse

Locations (1)

Franz-Volhard Clinical Research Center at the Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine

Berlin, Germany

Outcomes

Primary Outcomes

Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo

Time frame: Three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.